Cytiva officials say the company continues to expand its manufacturing capacity for bioprocessing single-use consumables in China. In collaboration with Wego Pharmaceutical in the country, the two firms are expanding an existing facility jointly launched in 2018. These newly added manufacturing lines will triple the supply capacity of single-use consumables in the Asia-Pacific region, according to Cytiva.

The planned expansion will consist of an additional eight new manufacturing lines, two of which are expected to launch by the end of 2021, with the other six lines scheduled in Q3 2022. It adds 1,300 m2 to the manufacturing area of the ISO Class 7 cleanroom and also includes a 1,200 m2 warehouse designed to further save lead time and increase flexibility for customers.

These expansions are part of the recently-announced 1.5 billion-dollar investment by Cytiva and Pall.

In addition to the increased capacity, Cytiva also brings new products, 100L to 1,000L Xcellerex mixer bags, to the expanded facility’s manufacturing portfolio. The new products will incorporate Fortem technology (Cytiva’s single-use characterized film).

“With the increases in global demand, customers require more flexibility and adaptability, resulting in the growing trend of in-region for-region manufacturing,” says Francis Van Parys, vice president, Asia-Pacific, Cytiva. “Our collaboration with Wego has proven successful for our customers in China, and this increased capacity will help the region improve manufacturing resilience with cost efficiencies and decreased lead times, while delivering an equivalent, high-quality product to our customers in the broader region.”

According to BioPlan Associates’ Annual Biomanufacturing report, the adoption of single-use technology is expected to increase rapidly in clinical production and in manufacturing. More than 85% of current pre-commercial and clinical manufacturing lines/facilities are single-use.

Previous articlePredicting Heart Failure Using the Plasma Proteome
Next articleShigella Enzyme Blocks Human Cell Death to Establish Infection